Shandong Huashang Chemical Co., Ltd.
Product
Cetilistat
  • Brand:HS
  • Model:25kg/drum
  • Purity:99%
  • Cas:282526-98-1
  • Createtime: 2026-04-14
  • Updatetime: 2026-04-15
Product Details
useage Industrial use
deliveryInfo
appearance powder
Molecular Weight 401.58
aliasen
supplyCapacity 50000MT/Month
harbor Qingdao,China
minorder 1KG
Appearance White crystalline powder

Shandong Huashang Chemical Co., Ltd. is a high-tech enterprise specializing in the research and development, manufacturing, and sales of fine chemicals. Headquartered in Jinan, Shandong, China, we are committed to delivering high-quality products to our global partners. Currently, over 90% of our products are exported to developed markets, including North America, Europe, Japan, South Korea, and the Middle East.

Basic Information

Product Name: Cetilistat
Alias: ATL-962; 2-(Hexadecyloxy)-6-methyl-4H-3,1-benzoxazin-4-one
CAS No. : 282526-98-1
Molecular Formula: C??H??NO?
Molecular Weight: 401.58 g/mol
Classification: Anti-obesity API; Pancreatic lipase inhibitor; Gastrointestinal lipase inhibitor

Physical & Chemical Properties

  • Appearance: White to off-white crystalline powder
  • Odor: Odorless
  • Melting Point: ~68–70 °C
  • Solubility: Insoluble in water; soluble in methanol, DMSO, acetonitrile (slightly)
  • Stability: Stable under dry & ambient conditions; light-sensitive, store sealed & dark
  • IC50 (Human pancreatic lipase): 5.95 nM (potent inhibitor)

Specification Table

Item Specification Unit Remarks
Product Name Cetilistat Anti-obesity API
CAS No. 282526-98-1 Pharma grade
Appearance White crystalline powder Fine powder
Molecular Formula C??H??NO? Benzoxazinone derivative
Molecular Weight 401.58 g/mol
Purity ≥98.0 % HPLC
Moisture ≤0.5 % Karl Fischer
Melting Point 68–70 °C

Main Uses

  1. Anti-obesity drug (API) — Potent, selective gastrointestinal/pancreatic lipase inhibitor; blocks triglyceride breakdown → reduces fat absorption → weight management.
  2. Hyperlipidemia treatment — Lowers serum triglycerides; for mixed hyperlipidemia & obesity-related metabolic disorders.
  3. Diabetes + obesity — Approved in Japan (2013, brand Oblean); Phase III in US; suitable for diabetic & non-diabetic obese patients.
  4. Research reagent — Tool for lipase study, obesity & metabolic syndrome research; impurity reference standard.

Mechanism of Action

  • Covalently binds active serine site of gastric/pancreatic lipases → enzyme deactivation.
  • Triglycerides not hydrolyzed → unabsorbed, excreted in feces → reduced calorie intake & body weight.

Packaging & Storage

  • Packaging: 1g/5g/25g/100g foil bag; 1kg aluminum can
  • Storage: 2–8 °C; sealed, dry, dark; away from moisture/strong light